About This Study
The purpose of this study is to learn if navtemadlin and ruxolitinib used together are safe and can help treat myelofibrosis. Researchers will look at how well the treatment works and how participants respond to it. This study is for volunteers who have been diagnosed with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) and have been taking the medicine ruxolitinib for at least 18 weeks without any response.
What Activities Are a Part of this Study?
- Informed Consent Review
- Use of Study Treatments or Placebo
- Use of Study Health Plans
- After Study Follow-Up Activities
- Review of Medical History
- Physical Examinations
- Phone Calls and/or Emails
- Study Visits and Consultations
- Surveys/Questionnaires
- Laboratory and Imaging Tests
- Specimen Sample Collection
Age & Gender
- 18 - 100+ years old
- Female
- Male
Language
- This study enrolls English and Spanish speakers
Additional Study Information
- No compensation provided
- Reimbursement offered
Study Locations
- Greater Charlotte, NC
- Greater Winston-Salem, NC